CoChat

Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?

Swinkels, D. W., Wetzels, J. F. M. · 2008 · Nephrology Dialysis Transplantation
Cited by 80

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The introduction of erythropoiesis-stimulating agents (ESA), such as recombinant human erythropoietin (EPO) has allowed effective treatment of anaemia in patients with chronic kidney disease (CKD). However, the optimal target level of haemoglobin is debated and many patients are resistant to ESA. Hepcidin is a recently discovered low-molecular-weight protein that plays an important role in iron metabolism. Hepcidin may be relevant in CKD and explain the often-observed disbalance in iron metabolism and the resistance to ESA. As such hepcidin could become an important tool to predict ESA responsiveness and to guide treatment with ESA and intravenous iron. In addition, hepcidin has the potential to become a target of treatment. In this review we summarize the pathophysiology of hepcidin and discuss its potential relevance for patients with CKD. Human hepcidin is produced by hepatocytes as an 84-amino-acid (aa) pre-prohepcidin [ 1 ]. Subsequent posttranslational processing results in the biologically active 25 aa form (hepcidin-25) that is secreted in the plasma. Additional amino-terminal degradation results in the production of two smaller isoforms (hepcidin-20 and -22), the biological significance of which is unknown [ 2 ]. Hepcidin is the key regulator of systemic iron homeostasis. Hepcidin leads to internalization and degradation of the iron exporter ferroportin, which is present on the cell surface of macrophages and enterocytes [ 3,4 ]. Thus, hepcidin inhibits the release of iron by macrophages and attenuates the iron uptake in the gut. In addition to these effects on body iron distribution, hepcidin might also directly inhibit erythroid-progenitor proliferation and survival [ 5 ]. Increased iron stores and inflammation induce hepcidin production, whereas hypoxia, anaemia, iron deficiency, increased erythropoiesis and ESA attenuate hepcidin synthesis [ 6–10 , Figure 1]. Thus, inflammation decreases the availability of iron, whereas hypoxia or anaemia increases iron release and absorption. Recent studies demonstrated that the hypoxia-inducible factor (HIF)-1 alpha contributes to the (down-) regulation of hepcidin, which was suggested to be a direct transcriptional mechanism [ 11 ] or mediated by muscle-derived soluble haemojuvelin, which may be increased by the HIF-dependent induction of furin activity [ 12 ]. However, the molecular mechanisms of the hypoxic or anaemic regulation of hepcidin are far from being understood. Several studies demonstrated that the induction of erythropoiesis and not hypoxia or anaemia itself down-regulates hepcidin [ 8 , 11–13 ]. ESA increase the erythropoietic activity, and thus iron must be rapidly mobilized from the stores to satisfy the needs of the bone marrow. The reported decrease in circulating hepcidin levels by ESA treatment [ 6 , 8 , 13 ] may explain the fast iron release. The relationship between hepcidin production and erythropoiesis suggests the presence of a regulator between the erythron and the liver, and several candidates for this role have been proposed, for example the soluble transferrin receptor (sTfR) [ 14,15 ] and the growth differentiation factor (GDF)-15 [ 16 ]. Until recently few investigative tools were available to measure hepcidin in human biological samples. Many studies measured the precursor prohepcidin using a commercially available ELISA. The relevance of these data is controversial because prohepcidin levels do not correlate with urinary and serum hepcidin, nor do they respond to relevant physiological stimuli [ 14 , 17–19 ]. Moreover, in vitro studies do not show a fixed relation between hepatocyte prohepcidin and hepcidin release [ 20 ]. Nevertheless, significant changes in prohepcidin concentration have been reported in ferroportin disease [ 21 ] and in patients with CKD [ 22–24 ]. Ganz and Nemeth et al . have developed a dot blot assay using non-commercially available antibodies for the semi-quantitative measurement of hepcidin in urine [ 25 ]. More recently, new assays have been developed exploiting novel technologies such as surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) and liquid chromatography tandem mass spectrometry (LC/MS-MS) [ 26–30 ]. With the use of internal standards these mass spectrometry techniques enable reliable quantitative hepcidin analysis in urine and serum (our unpublished data). To date, most studies have reported urinary hepcidin concentration. Although these urinary data nicely fit in the concept of hepcidin as the iron regulatory peptide [ 9,10 ] and concentrations of urine and serum highly correlate [ 27 ], we caution against the use of urine hepcidin measurements since urinary secretion of hepcidin will depend on glomerular filtration and tubular reabsorption. Furthermore hepcidin mRNA has been detected in the kidney, which suggests the potential for local production and release into the urine [ 31 ]. Thus, serum and urine levels can technically reliably be measure

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfn267

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 80

Metadata

Authors
Swinkels, D. W., & Wetzels, J. F. M.
Venue
Nephrology Dialysis Transplantation
Published
2008-04-02
Volume
23
Issue
8
Pages
2450-2453
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2108325722
Cited by
80
References
14
FWCI
5.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? https://app.cochat.ai/papers/10.1093/ndt/gfn267
The paper
Swinkels, D. W., & Wetzels, J. F. M. (2008). Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfn267

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.